Como Morrem os Doentes numa Enfermaria de Medicina Interna

Os doentes com doença crónica avançada são uma presença diária nas enfermarias de Medicina Interna, não existindo um protocolo de intervenção universal e uniforme. Este estudo pretende ser uma primeira abordagem para avaliar a forma como tratamos e cuidamos destes doentes, quer de etiologia neoplásica, quer de outras doenças crónicas, igualmente consumptivas, como dem��ncia, insuficiência cardíaca, VIH/SIDA, doença pulmonar crónica obstrutiva (DPCO). Foram recolhidas informações retrospectivas dos processos clínicos acerca das atitudes e tratamentos prestados a 285 doentes falecidos em 16 meses num hospital de agudos em Lisboa. A caracterização epidemiológica da população foi a esperada, com predom��nio de população idosa, dependente, com prevalência de doenças cardíacas e acidentes vasculares cerebrais (AVC), como diagnósticos principais, seguidas de dem��ncia e doenças respiratórias. Do total de falecimentos, 73% foram esperados, mas destes apenas 44% dos doentes estavam integrados em cuidados paliativos. A dor foi avaliada principalmente em doentes de foro neoplásico, sendo a analgesia administrada em 77% dos casos. A decisão de receberem cuidados paliativos foi discutida com a fam��lia em 26% dos doentes, mas não foi em nenhum caso discutido com o próprio doente. Consideramos que é necessário formação e informação para uma abordagem mais sistematizada do doente com doença crónica avançada e das suas necessidades. A definição explícita das expectativas de vida e uma abordagem sistem��tica da pesquisa de dor em todos estes, é necessária para garantir melhor qualidade dos cuidados prestados em fim de vida.

Analysis of Synaptic Proteins in the Cerebrospinal Fluid as a New Tool in the Study of Inborn Errors of Neurotransmission

Abstract In a few rare diseases, specialised studies in cerebrospinal fluid (CSF) are required to identify the underlying metabolic disorder. We aimed to explore the possibility of detecting key synaptic proteins in the CSF, in particular dopaminergic and gabaergic, as new procedures that could be useful for both pathophysiological and diagnostic purposes in investigation of inherited disorders of neurotransmission. Dopamine receptor type 2 (D2R), dopamine transporter (DAT) and vesicular monoamine transporter type 2 (VMAT2) were analysed in CSF samplesfrom 30 healthy controls (11 days to 17 years) by western blot analysis. Because VMAT2 was the only protein with intracellular localisation, and in order to compare results, GABA vesicular transporter, which is another intracellular protein, was also studied. Spearman’s correlation and Student’s t tests were applied to compare optical density signals between different proteins. All these synaptic proteins could be easily detected and quantified in the CSF. DAT, D2R and GABA VT expression decrease with age, particularly in the first months of life, reflecting the expected intense synaptic activity and neuronal circuitry formation. A statistically significant relationship was found between D2R and DAT expression, reinforcing the previous evidence of DAT regulation by D2R. To our knowledge, there are no previous studies on human CSF reporting a reliable analysis of these proteins. These kinds of studies could help elucidate new causes of disturbed dopaminergic and gabaergic transmission as well as understanding different responses to L-dopa in inherited disorders affecting dopamine metabolism. Moreover, this approach to synaptic activity in vivo can be extended to different groups of proteins and diseases.

Síndrome de Sjögren

O presente trabalho consta de duas partes estando incluída na primeira a revisão teórica e conceitos actuais sobre o tema e na segunda, a casuística do serviço de Estomatologia do Hospital Pulido Valente. De Abril de 1989 a 1991 (2 anos) vem sendo realizado um estudo sobre o Síndrome de SJÖGREN (Prim��rio e Secundário) de carácter multidisciplinar tendo tido a particular colaboração do Instituto Português de Reumatologia. Com este trabalho pretendemos demonstrar a importância da avaliação oral no estudo das doenças multissistémicas bem como estabelecer critérios de diagnóstico para a população portuguesa. Avaliámos 80 casos suspeitos de Síndrome Sjögren, 66 completamente estudados e cujo motivo da consulta foram a Xerostomia/Xeroftalmia/Hipertrofia das Glândulas parótidas, sintomas estes isolados ou em associação com outras patologias e após terem sido eliminadas outras causas dos mesmos. Tivemos que estabelecer os valores de referência salivares para a população portuguesa em 21 indivíduos voluntários e saudáveis (grupo de controle). A Xerostomia foi avaliada pela Sialoquímica, Sialografia, Cintigrafia e Biópsias do lábio inferior e da glândula sublingual. O exame oftalmológico foi efectuado no serviço de Oftalmologia do Hospital de Santo António dos Capuchos pelos testes de Schirmer, Rosa de Bengala e Ruptura Lacrimal. Apesar do Síndrome de Sjögren, até à presente data, estar muito pouco definido em relação à terapêutica, estes doentes necessitam de cuidados m��dicos e a Estomatologia tem um papel fundamental sob ponto de vista diagnóstico e terapêutico. Fica-se assim com a noção de que este síndrome não é tão infrequente como se poderia pensar e a avaliação da vertente oral é importante para o estabelecimento do grau da doença e seu tratamento.

The Role of Sensory Modulation Deficits and Behavioral Symptoms in a Diagnosis for Early Childhood

To contribute to the validation of the sensory and behavioral criteria for Regulation Disorders of Sensory Processing (RDSP) (DC:0-3R, 2005), this study examined a sample of toddlers in a clinical setting to analyze: (1) the severity of sensory modulation deficits and the behavioral symptoms of RDSP; (2) the associations between sensory and behavioral symptoms; and (3) the specific role of sensory modulation deficits in an RDSP diagnosis. Based on clinical observations, 78 toddlers were classified into two groups: toddlers with RDSP (N = 18) and those with‘‘other diagnoses in Axis I/II of the DC:0-3R’’ (OD3R; N = 60). The parents completed the Infant Toddler Sensory Profile and the Achenbach Checklist. The results revealed that the RDSP group had more severe sensory modulation deficits and specific behavioral symptoms; stronger, although not significant, associations between most sensory and behavioral symptoms; and a significant sensory modulation deficit effect. These findings support the validity of RDSP.

Validating Regulatory Sensory Processing Disorders Using the Sensory Profile and Child Behavior Checklist (CBCL 1 –5)

The objective was to validate Regulatory Sensory Processing Disorders’ criteria (DC:0-3R, 2005) using empirical data on the presence and severity of sensory modulation deficits and specific psychiatric symptoms in clinical samples. Sixty toddlers who attended a child mental health unit were diagnosed by a clinical team. The following two groups were created: toddlers with RSPD(N = 14) and those with ‘‘other diagnoses in Axis I/II of the DC:0-3R00(OD3R) (N = 46). Independently of the clinical process, parents completed the Infant Toddler Sensory Profile (as a checklist for sensory symptoms) and the Achenbach Behavior Checklist for ages 1/2–5 (CBCL 1/2–5). The scores from the two groups were compared. The results showed the following for the RSPD group: a higher number of affected sensory areas and patterns than in the OD3R group; a higher percentage of sensory deficits in specific sensory categories; and a higher severity of behavioral symptoms such as withdrawal, inattention, other externalizing problems and pervasive developmental problems in CBCL 1/2–5. The results confirmed our hypotheses by indicating a higher severity of sensory symptoms and identifying specific behavioral problems in children with RSPD. The results revealed convergent validity between the instruments and the diagnostic criteria for RSPD and supported the validity of RSPD as a unique diagnosis. The findings also suggested the importance of identifying sensory modulation deficits in order to develop an early intervention to enhance the sensory capacities of children who do not fully satisfy the criteria for some DSM-IV-TR disorders.

Cerebrospinal Fluid Synaptic Proteins as Useful Biomarkers in Tyrosine Hydroxylase Deficiency

Tyrosine hydroxylase (TH) deficiency is an inborn error of dopamine biosynthesis and a cause of early parkinsonism. Two clinical phenotypes have been described. Type “B”: early onset severe encephalopathy; type “A”: later onset, less severe and better response to L-dopa. We aimed to study the expression of several key dopaminergic and gabaergic synaptic proteins in the cerebrospinal fluid (CSF) of a series of patients with TH deficiency and their possible relation with the clinical phenotype and response to L-DOPA. Dopamine transporter (DAT), D2-receptor and vesicularmonoamine transporter (VMAT2)weremeasured in the CSF of 10 subjectswith THdeficiency byWestern blot analysis. In 3 patients, data of pre- and post-treatmentwith L-DOPA were available, and in one of them, GABA vesicular transporter was determined. Results were compared to an age-matched control population. The concentration of D2-receptors in CSFwas significantly higher in patients with TH deficiency than in controls. Similarly, DAT and vesicular monoamine transporter type 2 were up-regulated. Studies performed before LDOPA, and on L-DOPA therapy showed a paradoxical response with D2 receptor expression increase as L-Dopa doses and homovanillic concentration gradually raised in a B phenotype patient. The opposite results were found in two patients with A phenotype. However, this is a very small sample, and further studies are needed to conclude robust differences between phenotypes. Synaptic proteins are detectable in the CSF and their quantification can be useful for understanding the pathophysiology of neurotransmitter defects and potentially to adjust and personalize treatments in the future.

Undetectable Levels of CSF Amyloid-β Peptide in a Patient with 17β-Hydroxysteroid Dehydrogenase Deficiency

17β-hydroxysteroid dehydrogenase 10 (HSD10) deficiency is a rare X-linked inborn error of isoleucine catabolism. Although this protein has been genetically implicated in Alzheimer's disease pathogenesis, studies of amyloid-β peptide (Aβ) in patients with HSD10 deficiency have not been previously reported. We found, in a severely affected child with HSD10 deficiency, undetectable levels of Aβ in the cerebrospinal fluid, together with low expression of brain-derived neurotrophic factor, α-synuclein, and serotonin metabolites. Confirmation of these findings in other patients would help elucidating mechanisms of synaptic dysfunction in this disease, and highlight the role of Aβ in both early and late periods of life.